Humacyte (HUMA) Total Liabilities (2020 - 2026)

Humacyte (HUMA) has reported Total Liabilities for 7 consecutive years, with $106.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities fell 20.72% year-over-year to $106.8 million in Q2 2026; TTM through Jun 2026 was $106.8 million, a 20.72% decrease from a year earlier, with the FY2025 full-year figure at $113.3 million, down 40.56% from the prior year.
• Total Liabilities was $106.8 million for Q2 2026 at Humacyte, up from $98.9 million in the prior quarter.
• Over five years, Total Liabilities peaked at $190.5 million in Q4 2024 and troughed at $87.4 million in Q4 2022.
• A 5-year average of $124.6 million and a median of $112.8 million in 2023 frame the typical range for Total Liabilities.
• The widest YoY moves for Total Liabilities: up 830.5% in 2022, down 52.73% in 2022.
• Over 5 years, Total Liabilities stood at $87.4 million in 2022, then jumped by 31.25% to $114.7 million in 2023, then soared by 66.15% to $190.5 million in 2024, then tumbled by 40.56% to $113.3 million in 2025, then fell by 5.68% to $106.8 million in 2026.
• The last three Total Liabilities figures came in at $106.8 million (Q2 2026), $98.9 million (Q1 2026), and $113.3 million (Q4 2025), per Business Quant data.